Complete Mounjaro vs Wegovy Price and Clinical Comparison
Why UK Patients Choose EverydayMeds for Mounjaro vs Wegovy Weight Loss Decisions
When comparing Mounjaro vs Wegovy for weight loss, price transparency becomes a decisive factor for many UK patients. EverydayMeds stands apart by offering the lowest confirmed pricing on both treatments, with Wegovy starting at £79.99 for the 0.25mg starter dose. Unlike other providers who add consultation fees or delivery charges, our pricing includes everything—clinical assessment, prescriber review, prescription, and next-day cold-chain delivery.
The choice between these two prescription-only medicines often comes down to individual response, lifestyle factors, and budget considerations. Wegovy (semaglutide) works as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors as a dual agonist. Both require dose escalation over 16-17 weeks, but their storage requirements and injection schedules differ—factors that significantly impact long-term treatment costs and convenience.
Transparent Wegovy Pricing: No Hidden Costs for Mounjaro vs Wegovy Comparison
Our Wegovy pricing structure eliminates the guesswork when comparing Mounjaro vs Wegovy for weight loss costs. Single pen prices range from £79.99 (0.25mg starter) to £209.99 (2.4mg maintenance), with new customers applying code FIRST40 and returning customers using DOSE25 at checkout to secure these rates. These prices include full clinical assessment, prescriber review within 3 working days, and temperature-controlled next-day delivery.
Bundle options provide convenience for longer treatment periods, with our Intro Trio (0.25mg, 0.5mg, 1mg) priced at £299.99 covering the first 12 weeks of treatment. For patients reaching maintenance dosing, the Ultimate Stability Trio offers three months of 2.4mg supply at £649.99. All bundles include the same comprehensive service—no additional fees for multiple prescriptions or extended clinical monitoring throughout your weight management journey.
Clinical Evidence: Mounjaro vs Wegovy Weight Loss Trial Data
Understanding the clinical evidence helps inform the Mounjaro vs Wegovy for weight loss decision, though direct comparisons require careful interpretation due to different trial designs. Wegovy's STEP 1 trial demonstrated average weight loss of approximately 15% at 68 weeks when used alongside a reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). The SELECT trial further showed a 20% reduction in major cardiovascular events, adding significant clinical value beyond weight management.
Mounjaro's SURMOUNT trials indicated potentially higher average weight loss percentages, though these studies involved different patient populations and methodologies. Both treatments require 16-17 weeks of dose escalation to reach maintenance levels, and both show that weight regain may occur if treatment is discontinued. Your prescriber can help evaluate which option aligns best with your medical history and weight management goals.
How Wegovy Works in Mounjaro vs Wegovy Weight Loss Mechanisms
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking a natural hormone that regulates appetite and food intake. When administered as a once-weekly injection, it may reduce hunger signals in the brain whilst promoting feelings of fullness after smaller meals. This mechanism can lead to reduced calorie consumption without the intense hunger often experienced with traditional calorie restriction. The medication also slows gastric emptying, meaning food stays in the stomach longer, contributing to sustained satiety between meals. Unlike oral medications, the injectable format ensures consistent absorption and maintains therapeutic levels throughout the week.
Streamlined Ordering: Getting Started with Mounjaro vs Wegovy Weight Loss Treatment
Beginning your Mounjaro vs Wegovy for weight loss journey through EverydayMeds involves a simple three-step process designed for clinical safety and convenience. Complete our 3-minute online clinical assessment covering medical history, current medications, and weight management goals—this information helps prescribers determine suitability for either treatment option. Your assessment receives review within 3 working days (or 24 hours with express service), with prescribers available to discuss the Mounjaro vs Wegovy decision based on your individual circumstances. Once approved, your medication ships via next-day cold-chain delivery, maintaining the 2-8°C storage requirements essential for maintaining medication integrity and therapeutic effectiveness.
Storage and Practical Considerations: Mounjaro vs Wegovy Weight Loss Logistics
Storage requirements present a key practical difference when comparing Mounjaro vs Wegovy for weight loss management. Wegovy offers superior travel flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both use pre-filled FlexTouch pen systems for once-weekly injection, but Wegovy's extended room temperature stability makes it more suitable for frequent travellers or those with irregular schedules. Dose escalation follows similar timelines—starting at 0.25mg for 4 weeks, then increasing monthly until reaching maintenance levels. The 2.4mg maintenance dose requires ongoing refrigerated storage between injections, with each pen containing 4 weekly doses.
Cost-Per-Outcome Analysis: Mounjaro vs Wegovy Weight Loss Value Proposition
Evaluating the Mounjaro vs Wegovy for weight loss decision requires examining cost-per-outcome rather than just initial pricing. Wegovy's proven cardiovascular benefits from the SELECT trial add significant value for patients with weight-related cardiovascular risks, potentially reducing future healthcare costs. The medication's established NICE approval (TA875) and integration with specialist weight management services provide additional clinical support throughout treatment.
Long-term treatment costs favour the medication that provides sustainable results with minimal side effects for each individual patient. Wegovy's extensive safety profile, derived from over 4,000 patient-years of clinical trial data, offers reassurance for extended use. When calculating true treatment value, factor in consultation frequency, monitoring requirements, and the potential for dose adjustments—all included in EverydayMeds' transparent pricing structure for both treatment options.
Expert Prescriber Support: Making Your Mounjaro vs Wegovy Weight Loss Choice
The decision between Mounjaro vs Wegovy for weight loss benefits from expert clinical guidance, which EverydayMeds provides through our GPhC-registered prescribers (#9012878). Our clinical team evaluates factors including BMI, weight-related comorbidities, previous weight loss attempts, and lifestyle considerations to recommend the most appropriate treatment option. Both medications require ongoing monitoring for side effects and treatment response, with dose adjustments made based on individual tolerance and effectiveness. Professional support continues throughout your treatment journey, with prescribers available for questions about injection technique, managing side effects, or optimising your reduced-calorie diet and increased physical activity programme. Remember that both Wegovy and Mounjaro are available from EverydayMeds—your prescriber can help determine which option aligns best with your weight management goals and clinical profile.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
